# IMEXICA

ASX:IME

Medical Imaging Software

Corporate Presentation

### Disclaimer

The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants ("Information") is provided to the Recipient on the terms and conditions set out in this notice.

The Recipient should not treat the Information as advice relating to legal, taxation, financial product or investment matters and should consult their own advisers. This Presentation does not purport to contain all the information that a prospective investor may require. The Information may not be appropriate for all persons and it is not possible for ImExHS Limited to have regard to the investment objectives, financial situation and particular needs of each Recipient who reads or uses the Information. Accordingly, no recommendation or expression of opinion is contained within the Information. Further, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the Information, including the likelihood of achievement or reasonableness or any forecasts, prospects or returns contained in the Information. Before acting in reliance on any Information, the Recipient should conduct their own investigation and analysis in relation to the investment opportunity presented by this Presentation and should check the accuracy, reliability and completeness of the Information and obtain independent and specific advice from appropriate professional advisers.

Statements contained in the Information, particularly those regarding possible or assumed future performance or potential growth, prospects or projections of ImExHS Limited are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks, uncertainties and contingencies. The Information may also be subject to clarification and change and ImExHS Limited may in its absolute discretion, but without being under any obligation to do so, update, amend or supplement the Information.

The Information is for informational purposes only and does not constitute an offer to issue, or arrange to issue, securities or other financial products. The Information is not, and should not be construed to be, a Prospectus.


To the maximum extent permitted by law none of ImExHS Limited or its respective employees, agents or consultants nor any other person accepts any liability, including, without limitation, any liability arising out of fault of negligence, for any loss arising from the use of the Information.

# Company Highlights


- Next generation Radiology and Imaging Software platform
- Established in 2012
- Operations in Colombia, Mexico, Costa Rica, Ecuador and Peru
- \$14.5m total contracted value of revenue October 2018.

- Expansion into neighbouring LATAM countries with low risk go-to-market strategy
- First collaboration in Australia starting in 2018
- Additional cutting-edge functionality implemented- Web MPR/Web MIP - Two pilot sites deployed 4Q18, full commercial release 1Q19.
- Apply for FDA approval in 2018, ahead of USA soft launch in H1 2019


# Revenue – 5 Years



### **Total Contracted Value**



# Annualised Recurring Revenue



### Board & Key Management

#### TOM PASCARELLA Chairman

#### **Company Director**

- Experienced professional in Corporate & Investment Banking, focused on Credit Products, Structured Finance and M&A Advisory services. Since his time in banking, with Allen Partners Tom has focused on capital raising for asset managers and SMEs.
- Former CEO and Managing Director of Bank of America N.A. Sydney Branch.
- Fellow FinSIA, (Financial Services Institute of Australasia)
- Member of the Australian Institute of Company Directors

#### DR. GERMAN ARANGO CEO, Director

#### Professor of Neuro-Radiology

- Entrepreneur with > 10 years experience running Radiology businesses
- ImExHS Founder

#### ANDRES VANEGAS **Chief Sales Officer**

#### Mechatronic Engineer

- Specialist project and service manager in Radiology industry
- Over 10 years experience in deployment of imaging solutions for healthcare
- Ex-CTO Fujifilm Colombia

#### CARLOS PALACIO Non-Executive Director

#### Founder and CEO of CrossPoint **Telecommunications**

- Managed IT and Cloud provider to multinationals across 42 countries
- Major investor in ImExHS to date.
- B Eng, MBA (Macquarie)

#### DR. JORGE MARIN **Chief Medical Officer**

#### Professor of Neuro-Radiology

- Surgeon & Neuro-Radiologist Barcelona & Bogota
- Manages ImExHS's University collaboration business agreements

#### **HOWARD DIGBY**

Non-Executive Director

#### **Company Director**

- 25 year experience managing technology related businesses across Asia Pacific region
- Senior management roles at Adobe, Gartner, Economist Group
- B Eng (Hons) (UWA)

### Investment Overview

**DE-RISKED** 

High margin contracted future revenues

LEADING TECHNOLOGY

Next generation workflow and image management solution for healthcare facilities, built by radiologists, for radiologists

**PROVEN** 

Successfully demonstrated market penetration into Mexico, Ecuador, Peru and Costa Rica with post-raising strategies for rapid expansion in LATAM and Asia-Pacific

SALES PIPELINE

Strong sales pipeline, including renewals will add to existing contracted revenue

FUNDING

Funding largely dedicated to expansion, rather than technical development

### Market Overview


GEOGRAPHY	MARKET (US\$m) <sup>1</sup>	GROWTH (CAGR) <sup>1</sup>
LATAM	417	8.1%
APAC	695	7.0%
North America	1,667	4.4%
Europe	967	5.8%
Other	236	6.8%
TOTAL	3,982	5.8%

- Escalating healthcare costs in all markets are driving demand for cost effective solutions
- Large percentage of radiology systems in developing countries use archaic analogue work flows, creating churn event opportunity to migrate to nextgeneration digital cloud solution
- Demand for web based TeleRadiology is growing rapidly (predicted CAGR of 21%<sup>2</sup>)
- The application of Artificial Intelligence to radiological interpretation creates opportunities on numerous fronts
- ImExHS is initially targeting sales expansion into neighbouring LATAM markets to where ImExHS currently operates, followed closely by APAC, then North America and finally Europe


<sup>&</sup>lt;sup>1</sup> Acute Market Report (2015), Picture Archiving Communication Systems (PACS) & Radiology Information Systems (RIS), Growth, Future Prospects & Competitive Analysis, 2016 - 2026 <sup>2</sup> Future Market Insights (2017), Global Teleradiology Market Industry Analysis and Opportunity Assessment, 2016-2026

# Market Opportunity - Immediate

#### TOTAL HOSPITALS - PUBLIC VS PRIVATE



### What We Do



<sup>&</sup>lt;sup>1</sup> Tele-Radiology - radiology concerned with the transmission of digitised medical images (as X-rays, CT scans, and sonograms) over electronic networks and with the interpretation of the transmitted images for diagnostic purposes

# Supporting Radiologists

#### Hiruko supporting the efficiency and user experience for Radiologists

- Radiologists can
  - o work from anywhere, on any device or browser
  - customise Hiruko to their own requirements and preferences
- The fully integrated nature of Hiruko increases both the speed and efficiency of the Radiology workflow
  - No need for the Radiologist to jump between different applications and windows
  - Second opinions can be sought from Colleagues regardless of what platform they use
- The Radiologist can use voice recognition (clinical language understanding) to append the diagnosis to the image, from anywhere on any device
- Hiruko has integrated billing including support for publically funded health insurance programs (similar to Medicare)

### How We Do It

### Modular

Able to grow and scale as scan volumes increase and as new diagnostic scanners or radiology facilities are added

### Independent System

Hiruko can run on any infrastructure - private or public cloud and even on the customer's own dedicated server infrastructure

### API Enabled

Easy to integrate with other customer or third party systems to extend its value in the customer environment

.... Compared to most RIS PACS solutions which are built on heavy, inflexible and expensive client server architecture.

### Business Model

### Revenue Contracts



Software as a Service (SaaS)
 year contacts (paid monthly)



2. Platform as a Service (PaaS)3-5 year contacts (paid monthly)



3. One-off Sales & Maintenance Paid in Full

### Target Geographies

LATAM (Now)

APAC (Next)

USA, Europe, Australia (Market Driven)

### Target Verticals

#### HEALTH CARE FACILITIES

Private Hospitals

Public Hospitals

Private Radiology



### Distribution Model

#### DIRECT SALES

Global Growth developing branches in each new country

Cloud Market Place Globally

Augment with channel strategy

#### CHANNELS

Specialist Distributors

**TELCOs** 

OEMs

White Label

### ImExHS Today – Value Proposition & Competitive Advantage

## Radiology businesses (hospitals & clinics) prefer the ImExHS Hiruko platform because:

- Exceeds the capability & usability of competing high end platforms – Integrated Business Intelligence
- Disruptive price point up to 75% cheaper than competitors
- Cloud-based with zero in-house IT impact
- Single end to end solution including integrated scheduling and billing tools; avoid integration of multiple solutions
- Supports non-standard file formats that have clinical significance

# Radiologists love the ImExHS Hiruko platform because they can:

- Work from anywhere, using any device (Mac, PC, tablet or smartphone)
- Use speech recognition with full Clinical Language understanding embedded in the application
- Use post-processing of images to aid in diagnosis
- Efficiently consult with colleagues for second opinions
- Hiruko software is fast, stable and easy to access

### ImExHS Today – Customer & Revenue Base

### Solutions are fully developed, validated & proven:

- ImExHS has deployed >200 sites in LATAM
  - o 71 Hospitals
  - o 180 Clinics
  - > 35,000 clinical devices
  - o 190 Customers
  - o 5 Countries
- > 4.5 million new radiological studies per annum
- Used by over 600 Radiologists

### ImExHS Today – Channel Partners



### New Product Verticals

TESTING	DEVELOPMENT	PILOT	COMMERCIAL
		PATHOLOG	Y
	CA	RDIOLOGY	



### Commercialisation

- RADIOLOGY
   Q4 2018 Web MPR & MIP, triangulation tool implemented. 2 Pilot sites deployed.
   Q2 2019 Web 3D release
- ANATOMICAL PATHOLOGY
   Q4 2017 Secured first commercial customer
   Q3 2018 2<sup>nd</sup> Pilot test customer commenced
   Q1 2019 Full Commercial launch
- CARDIOLOGY
   Q1 2018 Pilot testing at Las Americas (VNA installed)
   Q3 2018 Develop information work platform
   Q4 2018 Commercial launch

### Artificial Intelligence

- NATURAL LANGUAGE PROCESSING ALGORITHMS
   Specified pathologies
   Predictive Diagnostic alerts
   Diagnostic concordance analysis
- MACHINE LEARNING ALGORITHMS
   Tumour Segmentation and Classification
   Lung Nodule detection
   Bone Fracture severity identification
- AUTOMATIC IMAGE ANNOTATION RECOMMENDATIONS

### Research

- BRAVIZ v2.0
   Platform for advanced analytics and visualisation of neurological images
- NEW VISUALISATION TOOLS
   Analytics on visual presentation

# ImExHS Tomorrow – New Markets

	2018	2019			
	Q4	Q1	Q2	Q3	Q4
LATAM					
Brazil		Appoint Distributor		Launch	
Other South America	Appoint Distributor	Launch			
Other Central America	Appoint Distributor	Launch			
APAC					
Phillipines		Appoint Distributor Laund		Launch	
Australia	Pilot				
APAC 2				Rele	ease
APAC 3		Release		ease	
NORTH AMERICA					
FDA	Submit	Аррг	roval		
USA				Soft Launch	

# Medical Imaging Corporate Activity

























### January 2018

UK-private equity
Permira Healthcare
paid \$1.3bn
consideration for IMed Radiology,
Australia's largest
medical imaging
clinic network

### November 2017

Philips (mkt cap \$47bn) and Nuance (mkt cap \$6.6bn) joint-venture to bring Al into radiology reporting

#### November 2017

Amazon (mkt cap \$843bn) partnering with Cerner Health (mkt cap \$28bn) to analyse clinical data and predict treatments using AWS cloud-hosted data

### May 2017

GE Health (mkt cap \$175b) and Partners HealthCare (\$12bn Revenue) 10-year joint-venture to build Al software across medical imaging software process

### February 2016

IBM acquired Truven
Health for \$3.3bn to
buy cloud-based
healthcare data,
analytics and insights
on 200 million people

### August 2015

Healthcare for \$1.25bn for medical image patient data across 7,500 US healthcare sites

# Public Company Comparables

	VOLPARA (ASX:VHT)	PRO MEDICUS (ASX:PME)	ImExHS (ASX:IME)
Description	Breast X-ray imaging, transitioning to SaaS based contracts	Radiology imaging software, strong 5 year contracted revenue order book	Radiology imaging software, High growth SaaS/PaaS based revenue
Market Cap (\$m)	\$254m <sup>1</sup>	\$1,060m <sup>1</sup>	\$34m <sup>1</sup>
Cash	\$18.5m <sup>2</sup>	\$25.2m <sup>3</sup>	\$4.8m <sup>2</sup>
Revenue Growth rate (FY <sub>t</sub> v FY <sub>t-1</sub> )	18,7%	13.8%	37%
TRADING			
Estimated Total Contracted Value	N/A <sup>3</sup>	\$135m <sup>3</sup>	\$14.5m <sup>4</sup>
Multiple		7.9x	2.4x
Annualised Recurring Revenue	\$4.4m <sup>2</sup>	29.13*	\$3.8m <sup>4</sup>
Multiple	57.9.2x	36.4x*	9.0x
HISTORICALS			
FY18 Revenue	\$2.6m <sup>5</sup>	\$35.9m <sup>3</sup>	\$4.5m
Multiple	98.8x	29.5x	7.6x

<sup>&</sup>lt;sup>1</sup>08 November 2018

<sup>&</sup>lt;sup>2</sup> 30 September 2018

<sup>&</sup>lt;sup>3</sup> Not available

<sup>&</sup>lt;sup>4</sup> 31 October 2018

<sup>&</sup>lt;sup>5</sup> 31 March 2018

<sup>\*</sup> Recurring revenue for FY18 period

## Investment Highlights

- DE-RISKED
   Significant annualised recurring revenue of \$3.8m
- LEADING TECHNOLOGY
   Next generation workflow and image management solution for Healthcare Facilities, built by radiologists, for radiologists
- PROVEN
   Successfully demonstrated market penetration into Mexico,
   Ecuador, Peru and Costa Rica with post-raising strategies for rapid expansion in LATAM and Asia-Pacific
- SALES PIPELINE
   Strong sales pipeline to support \$14.5m revenue in total contracted value
- FUNDING
   Funding largely dedicated to expansion, rather than technical development

